| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0781
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de79084abaceee7ae83dcd49ec4866e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12cdb8647fd1da3ceb0b44d8ce0e01b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e62a20e6d6f4d53ed2b23815671642d |
| publicationDate |
2017-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017019800-A |
| titleOfInvention |
Excellent effect of CD37 antibody on CLL blood sample |
| abstract |
An antibody for the treatment of high-risk patients suffering from a B-cell malignancy and a pharmaceutical composition comprising the antibody are provided. CD37 antibodies for the treatment of high-risk patients suffering from B-cell malignancies. Medicament comprising CD37 antibody or CD37 antibody for use in the treatment of high-risk patients suffering from a B-cell malignancy, preferably for use in the treatment of high-risk patients with chronic lymphocytic leukemia (CLL) Composition. High-risk patients may be selected from the group consisting of patients resistant to fludarabine treatment, patients with TP53 dysfunction, patients with 17p13 deletion, and patients no longer responding to rituximab treatment. [Selection figure] None |
| priorityDate |
2010-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |